Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Erstveröffentlichung
2017
Wissenschaftlicher Artikel
Published in
Circulation ; 136 (2017), 3. - S. 249+. - ISSN 0009-7322. - eISSN 1524-4539
Link to publication
https://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190Faculties
Medizinische FakultätInstitutions
Institut für Epidemiologie und Medizinische BiometrieSubject headings
[Free subject headings]: canagliflozin | dapagliflozin | death | diabetes mellitus | empagliflozin | heart failure | sodium glucose transporter 2 | diabetes-mellitus | mortality | association | metaanalysis | prevalence | mechanisms | diagnosis | accuracy | register | disease[DDC subject group]: DDC 610 / Medicine & health